http://www.astrazeneca.com/ Subscribe to AstraZeneca news via RSS http://www.astrazeneca.com/?itemId=4477598 AstraZeneca today announced the company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) asking for additional information for the supplemental New Drug Application for SEROQUEL XR (quetiapine fumarate) Extended Release Tablets for the treatment of Major Depressive Disorder (MDD) in adult patients. Wed, 24 Dec 2008 07:00:00 GMT http://www.astrazeneca.com/?itemId=4477598 2008-12-24T07:00:00Z http://www.astrazeneca.com/?itemId=4440167 AstraZeneca and MAP Pharmaceuticals, Inc. announced today an exclusive worldwide agreement to develop and commercialise Unit Dose Budesonide (UDB), MAP Pharmaceuticals’ proprietary nebulised formulation of budesonide. UDB is being developed by MAP Pharmaceuticals as a potential treatment for paediatric asthma and is currently in Phase III clinical development. UDB has the potential to be nebulised more quickly and at a lower nominal dose than the commercially available product. Fri, 19 Dec 2008 12:00:37 GMT http://www.astrazeneca.com/?itemId=4440167 2008-12-19T12:00:37Z http://www.astrazeneca.com/?itemId=4401886 AstraZeneca Responds to FDA Joint Advisory Committees’ Recommendation on Symbicort Thu, 11 Dec 2008 11:00:37 GMT http://www.astrazeneca.com/?itemId=4401886 2008-12-11T11:00:37Z http://www.astrazeneca.com/?itemId=4394085 AstraZeneca today announced that it has returned worldwide rights to Infinity Pharmaceuticals for the development and commercialisation of Infinity’s heat shock protein 90 (Hsp90) drug candidates IPI-504 (MEDI-561) and IPI-493, in development for the treatment of cancer and related conditions. Thu, 11 Dec 2008 10:00:37 GMT http://www.astrazeneca.com/?itemId=4394085 2008-12-11T10:00:37Z http://www.astrazeneca.com/?itemId=4376018 AstraZeneca and Targacept, Inc. today announced top-line results from a Phase IIb clinical trial of AZD3480 (TC-1734) conducted by AstraZeneca in cognitive dysfunction in schizophrenia (CDS), known as the HALO trial. Mon, 08 Dec 2008 21:00:37 GMT http://www.astrazeneca.com/?itemId=4376018 2008-12-08T21:00:37Z http://www.astrazeneca.com/?itemId=4369714 AstraZeneca and Bristol-Myers Squibb today announced expansion of their worldwide collaboration to include the development and commercialisation of dapagliflozin in Japan. Dapagliflozin, one of two investigational drugs under joint development by the companies, is currently being studied in Phase III clinical trials in several countries, including the U.S., to assess its efficacy and safety as a once-daily treatment for type 2 diabetes. Mon, 08 Dec 2008 12:00:37 GMT http://www.astrazeneca.com/?itemId=4369714 2008-12-08T12:00:37Z http://www.astrazeneca.com/?itemId=4334744 AstraZeneca and POZEN Inc., co-development partner for the investigational compound PN 400, have announced today results from two Phase III studies, PN 400-301 and PN 400-302 comparing PN 400 (enteric-coated naproxen 500 mg and immediate release esomeprazole 20 mg) to enteric-coated naproxen 500 mg. These studies were conducted by POZEN under an agreed Special Protocol Assessment (SPA) with the FDA. Wed, 03 Dec 2008 07:00:37 GMT http://www.astrazeneca.com/?itemId=4334744 2008-12-03T07:00:37Z http://www.astrazeneca.com/?itemId=4273019 AstraZeneca today announced that MedImmune, its wholly owned biologics business, has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) asking for additional information on motavizumab. The CRL is in connection with the Biologics License Application (BLA) for motavizumab for the prevention of serious respiratory syncytial virus (RSV) disease, which was submitted on 30 January 2008. Motavizumab is an investigational monoclonal antibody (MAb). Fri, 28 Nov 2008 07:00:37 GMT http://www.astrazeneca.com/?itemId=4273019 2008-11-28T07:00:37Z http://www.astrazeneca.com/?itemId=4251198 AstraZeneca today announced it has entered into a settlement agreement in its Pulmicort Respules patent infringement litigation against Ivax Pharmaceuticals, Inc., a wholly owned subsidiary of Teva Pharmaceuticals USA. Tue, 25 Nov 2008 20:00:37 GMT http://www.astrazeneca.com/?itemId=4251198 2008-11-25T20:00:37Z http://www.astrazeneca.com/?itemId=4241742 On 19 November 2008, AstraZeneca entered into an agreement with Abraxis BioScience, LLC, under which, subject to the satisfaction of terms and conditions thereof, Abraxis would re-acquire exclusive rights to market ABRAXANE in the United States. Tue, 25 Nov 2008 09:00:37 GMT http://www.astrazeneca.com/?itemId=4241742 2008-11-25T09:00:37Z http://www.astrazeneca.com/?itemId=4216057 AstraZeneca today announced the divestment to GlaxoSmithKline of a portfolio of over-the-counter (OTC) products predominantly sold in Sweden. The decision reinforces AstraZeneca’s strategy to focus on innovation in prescription medicines. Thu, 20 Nov 2008 17:56:37 GMT http://www.astrazeneca.com/?itemId=4216057 2008-11-20T17:56:37Z http://www.astrazeneca.com/?itemId=4215747 AstraZeneca has today announced proposed changes to its global manufacturing and supply chain operations as part of its ongoing programme to improve efficiency across the business. The introduction of new manufacturing processes has brought further opportunities to drive efficiencies across the global supply chain. The company will also establish a regional packing strategy, to improve its ability to respond to customer requirements, while equipping the business for emerging markets growth. Thu, 20 Nov 2008 17:21:22 GMT http://www.astrazeneca.com/?itemId=4215747 2008-11-20T17:21:22Z http://www.astrazeneca.com/?itemId=4215773 On 19 November 2008, AstraZeneca was granted a Temporary Restraining Order (TRO) by the United States District Court for the District of New Jersey, halting sales of Teva’s budesonide inhalation suspension product, a generic version of AstraZeneca’s PULMICORT RESPULES treatment. Thu, 20 Nov 2008 17:16:03 GMT http://www.astrazeneca.com/?itemId=4215773 2008-11-20T17:16:03Z http://www.astrazeneca.com/?itemId=4179301 AstraZeneca today announced that the once-daily formulation SEROQUEL XR (quetiapine fumarate extended release tablets) and SEROQUEL (quetiapine fumarate) have been approved under the European Mutual Recognition Procedure (MRP) for new indications in bipolar disorder. SEROQUEL XR and SEROQUEL have been approved for the treatment of major depressive episodes in bipolar disorder. Additionally, SEROQUEL XR has been licensed for moderate to severe manic episodes in bipolar disorder. Thu, 13 Nov 2008 13:30:00 GMT http://www.astrazeneca.com/?itemId=4179301 2008-11-13T13:30:00Z http://www.astrazeneca.com/?itemId=4179306 New data from the JUPITER study demonstrated that CRESTOR® (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels. Sun, 09 Nov 2008 09:30:00 GMT http://www.astrazeneca.com/?itemId=4179306 2008-11-09T09:30:00Z http://www.astrazeneca.com/?itemId=4084119 AstraZeneca today announced that John Patterson, Executive Director, Development will retire from the company in March 2009. Tue, 04 Nov 2008 11:00:00 GMT http://www.astrazeneca.com/?itemId=4084119 2008-11-04T11:00:00Z http://www.astrazeneca.com/?itemId=4179310 AstraZeneca has delivered a robust set of results, and on the back of this, is raising financial guidance for the full year. Additionally good progress is being made on reshaping the cost base, including advancing innovation in research and development activities with greater productivity and efficiency. Thu, 30 Oct 2008 00:00:00 GMT http://www.astrazeneca.com/?itemId=4179310 2008-10-30T00:00:00Z http://www.astrazeneca.com/?itemId=4179314 AstraZeneca today announced its submission of SEROQUEL XR (quetiapine fumarate extended release tablets) to European regulatory authorities seeking approval for both short-term and maintenance treatment of Generalised Anxiety Disorder (GAD). This is the first time approval has been sought in Europe for an atypical antipsychotic medicine for the treatment of GAD. Mon, 20 Oct 2008 23:00:00 GMT http://www.astrazeneca.com/?itemId=4179314 2008-10-20T23:00:00Z http://www.astrazeneca.com/?itemId=4179318 AstraZeneca and POZEN Inc., co-development partner for the investigational compound PN 400, have announced today that the U.S. Food and Drug Administration (FDA) has informed POZEN that it is conducting an internal review on the acceptability of endoscopic gastric ulcers as a primary endpoint in clinical studies. The FDA has not indicated when their internal review will be completed, although an FDA internal meeting has been scheduled to review this subject during the first quarter of 2009. Fri, 17 Oct 2008 09:00:00 GMT http://www.astrazeneca.com/?itemId=4179318 2008-10-17T09:00:00Z http://www.astrazeneca.com/?itemId=4179322 AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets for the acute treatment of the depressive episodes associated with bipolar disorder, the manic and mixed episodes associated with bipolar I disorder, and the maintenance treatment of bipolar I disorder as adjunctive therapy to lithium or divalproex. Thu, 09 Oct 2008 23:00:00 GMT http://www.astrazeneca.com/?itemId=4179322 2008-10-09T23:00:00Z http://www.astrazeneca.com/?itemId=4179326 AstraZeneca today announced that the US District Court for the District of New Jersey has denied Teva’s Motion for Summary Judgment of no infringement in the PULMICORT RESPULES (budesonide inhalation suspension) patent litigation. Tue, 23 Sep 2008 23:00:00 GMT http://www.astrazeneca.com/?itemId=4179326 2008-09-23T23:00:00Z http://www.astrazeneca.com/?itemId=4179330 Results inconclusive, as primary outcome measure not statistically significant for either donepezil or AZD3480; results impacted by improvement in placebo group Improvements shown on secondary outcome measures ADCS-CGIC and MMSE Overall safety and tolerability profile comparable to placebo, with fewer GI-related AEs than donepezil Next steps include further analysis of full dataset and planned discussions with leading medical experts Tue, 16 Sep 2008 10:00:00 GMT http://www.astrazeneca.com/?itemId=4179330 2008-09-16T10:00:00Z http://www.astrazeneca.com/?itemId=4179750 AstraZeneca today announced that Rudy Markham is to join the Board of Directors as a Non-Executive Director with immediate effect. Rudy Markham was formerly Chief Financial Officer of Unilever. He is currently a Non-Executive Director of Legal and General Group Plc, Standard Chartered PLC and United Parcel Service, Inc. He is also a member of Board of the Financial Reporting Council. Fri, 12 Sep 2008 10:00:00 GMT http://www.astrazeneca.com/?itemId=4179750 2008-09-12T10:00:00Z http://www.astrazeneca.com/?itemId=3892288 New data presented for the first time at EASD 2008 Saxagliptin with metformin as initial combination therapy lowered A1C Improvements demonstrated across key measures of glucose control studied in treatment-naïve people with type 2 diabetes Tue, 09 Sep 2008 09:00:00 GMT http://www.astrazeneca.com/?itemId=3892288 2008-09-09T09:00:00Z http://www.astrazeneca.com/?itemId=3892290 Results from two 24-week Phase III studies presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrate that saxagliptin produced reductions across all key measures of glucose control studied [glycosylated hemoglobin level (A1C), fasting plasma glucose (FPG) and postprandial glucose (PPG)] when added to a sulphonylurea (SU) or a thiazolidinedione (TZD) in people with inadequately controlled type 2 diabetes, compared with placebo added to either an increased dose of SU or a Mon, 08 Sep 2008 10:00:00 GMT http://www.astrazeneca.com/?itemId=3892290 2008-09-08T10:00:00Z http://www.astrazeneca.com/?itemId=3892236 AstraZeneca and Abbott announced today that they have entered into an agreement for Abbott to promote AstraZeneca's CRESTOR® (rosuvastatin calcium), a medication used along with diet to reduce high cholesterol. Thu, 14 Aug 2008 01:00:00 GMT http://www.astrazeneca.com/?itemId=3892236 2008-08-14T01:00:00Z http://www.astrazeneca.com/?itemId=3892298 AstraZeneca corporate information, one of the world's leading pharmaceutical companies providing effective prescription drugs and innovative prescription medicines in many important therapeutic areas Wed, 30 Jul 2008 23:00:00 GMT http://www.astrazeneca.com/?itemId=3892298 2008-07-30T23:00:00Z http://www.astrazeneca.com/?itemId=3892302 AstraZeneca and Bristol-Myers Squibb Company today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) on June 30th and validation of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for ONGLYZA™ (saxagliptin). Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor, is an investigational drug under joint development by AstraZeneca and Bristol-Myers Squibb for the treatment of type 2 diabetes. The companies have Wed, 23 Jul 2008 11:00:00 GMT http://www.astrazeneca.com/?itemId=3892302 2008-07-23T11:00:00Z http://www.astrazeneca.com/?itemId=3892294 AstraZeneca today announced that the US District Court for the District of New Jersey has granted the company's Motion for Summary Judgment of No Inequitable Conduct. AstraZeneca had sued Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging infringement of AstraZeneca's patent as a result of Teva's and Sandoz's filings of Abbreviated New Drug Applications (ANDAs). The ANDAs sought approval to market generic versions of SEROQUEL (quetiapine fumarate) tablets in the US before SEROQUEL's patent Tue, 01 Jul 2008 23:00:00 GMT http://www.astrazeneca.com/?itemId=3892294 2008-07-01T23:00:00Z http://www.astrazeneca.com/?itemId=3892262 AstraZeneca today announced that Dave Mott, President and Chief Executive Officer (CEO) of its biologics business unit, MedImmune, has decided to leave the company at the end of July. Tony Zook, CEO of AstraZeneca’s North American business and Executive Vice President of Global Marketing, has been appointed as head of MedImmune on an interim basis until a permanent successor is identified. Thu, 26 Jun 2008 02:00:00 GMT http://www.astrazeneca.com/?itemId=3892262 2008-06-26T02:00:00Z http://www.astrazeneca.com/?itemId=3892260 AstraZeneca and Columbia University Medical Center in New York today announced that they have entered into a strategic research collaboration in metabolic related diseases, to develop novel therapeutics primarily in type 2 diabetes and obesity and, with a secondary focus on atherosclerosis (hardening of the arteries)/dyslipidaemia (abnormal blood lipid levels). Tue, 17 Jun 2008 14:15:00 GMT http://www.astrazeneca.com/?itemId=3892260 2008-06-17T14:15:00Z http://www.astrazeneca.com/?itemId=3892258 AstraZeneca today announced that the company has submitted applications in the European Union (EU) for once-daily SEROQUEL XR™ (quetiapine fumarate) Extended-Release Tablets (quetiapine XR), seeking approval for the treatment of major depressive disorder (MDD) including maintenance therapy in adult patients using the Mutual Recognition Procedure (MRP). This follows a supplementary New Drug Application (sNDA) submission for SEROQUEL XR in MDD in the U.S. in February this year. Tue, 10 Jun 2008 06:00:00 GMT http://www.astrazeneca.com/?itemId=3892258 2008-06-10T06:00:00Z http://www.astrazeneca.com/?itemId=3892264 AstraZeneca today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for approval of a new indication for SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the long-term maintenance treatment of asthma in paediatric patients ages 6 to 11 years old. SYMBICORT is currently approved for the long-term maintenance treatment of asthma in patients 12 years and older. Wed, 04 Jun 2008 05:00:00 GMT http://www.astrazeneca.com/?itemId=3892264 2008-06-04T05:00:00Z http://www.astrazeneca.com/?itemId=3892309 AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL® (quetiapine fumarate) for the maintenance treatment of patients with bipolar I disorder, as adjunct to lithium or divalproex. SEROQUEL is approved by the FDA for the treatment of schizophrenia, and is also the only single agent approved by the FDA for the treatment of both depressive episodes in bipolar disorder and acute manic episodes associated with bipolar I disorder. Tue, 13 May 2008 23:00:00 GMT http://www.astrazeneca.com/?itemId=3892309 2008-05-13T23:00:00Z http://www.astrazeneca.com/?itemId=3892314 AstraZeneca today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for SEROQUEL XR™ (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of generalised anxiety disorder (GAD), including maintenance of antianxiety effect. It is the first time approval has been sought for an atypical antipsychotic medicine in GAD. Thu, 08 May 2008 08:30:00 GMT http://www.astrazeneca.com/?itemId=3892314 2008-05-08T08:30:00Z http://www.astrazeneca.com/?itemId=3892306 AstraZeneca today announced that the European Patent Office (EPO) Technical Board of Appeal has made a final ruling that the European Combination patent covering the use of Symbicort® (formoterol and budesonide) for the treatment of chronic obstructive pulmonary disease (COPD) (EPB1014993) has been revoked, following an appeal from generic manufacturers Norton Healthcare and Generics UK. Mon, 05 May 2008 23:00:00 GMT http://www.astrazeneca.com/?itemId=3892306 2008-05-05T23:00:00Z http://www.astrazeneca.com/?itemId=3892311 AstraZeneca today announced the submission of a marketing authorisation application to the European Medicines Agency (EMEA) for its oral anti-cancer drug, gefitinib (IRESSA™) as a treatment for locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have been pre-treated with platinum-containing chemotherapy. Fri, 02 May 2008 12:30:00 GMT http://www.astrazeneca.com/?itemId=3892311 2008-05-02T12:30:00Z http://www.astrazeneca.com/?itemId=3892252 AstraZeneca today announced submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) to seek approval of a new indication for SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). SYMBICORT is currently approved for the long-term maintenance treatment of asthma in patients 12 years and older. Wed, 30 Apr 2008 05:00:00 GMT http://www.astrazeneca.com/?itemId=3892252 2008-04-30T05:00:00Z http://www.astrazeneca.com/?itemId=3892254 "Underlying business performance on track to achieve full year financial targets. Core EPS target increased to reflect year to date currency impact." Wed, 23 Apr 2008 23:00:00 GMT http://www.astrazeneca.com/?itemId=3892254 2008-04-23T23:00:00Z http://www.astrazeneca.com/?itemId=3892250 AstraZeneca today announced it has entered into a settlement agreement in its Nexium patent infringement litigation against Ranbaxy Laboratories Ltd. and its affiliates (“Ranbaxy”). Tue, 15 Apr 2008 04:00:00 GMT http://www.astrazeneca.com/?itemId=3892250 2008-04-15T04:00:00Z http://www.astrazeneca.com/?itemId=3892320 AstraZeneca today announced it has decided to stop the CRESTOR JUPITER clinical study early based on a recommendation from an Independent Data Monitoring Board and the JUPITER Steering Committee, which met on March 29, 2008. The study will be stopped early because there is unequivocal evidence of a reduction in cardiovascular morbidity and mortality amongst patients who received CRESTOR when compared to placebo. Sun, 30 Mar 2008 23:00:00 GMT http://www.astrazeneca.com/?itemId=3892320 2008-03-30T23:00:00Z http://www.astrazeneca.com/?itemId=3892324 AstraZeneca today announced a collaboration with Silence Therapeutics plc, focused on the development of a range of novel approaches for the delivery of short interfering ribonucleic acid (siRNA) molecules. The deal builds on Silence Therapeutics’ expertise in the delivery of siRNA molecules, in particular its success with the functional systemic delivery of siRNA in vivo using its proprietary AtuPLEX technology. The financial details of this collaboration, in which both parties will contribute expertise, Thu, 13 Mar 2008 00:00:00 GMT http://www.astrazeneca.com/?itemId=3892324 2008-03-13T00:00:00Z http://www.astrazeneca.com/?itemId=3892318 AstraZeneca today announced a trial date has been set for patent litigation in the US District Court for the District of New Jersey against Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging infringement of AstraZeneca’s patent as a result of Teva’s and Sandoz’s filings of Abbreviated New Drug Applications (ANDAs). The ANDAs seek approval to market generic versions of SEROQUEL® (quetiapine fumarate tablets) in the US before SEROQUEL’s patent expires in 2011. The Court has set a date for Wed, 12 Mar 2008 00:00:00 GMT http://www.astrazeneca.com/?itemId=3892318 2008-03-12T00:00:00Z http://www.astrazeneca.com/?itemId=3892322 In response to the growing burden of cancer in the developing world, AstraZeneca, in partnership with Tikur Anbessa Hospital, Addis Ababa, The Ethiopian Ministry of Health and AXIOS, developed a framework two years ago for the first-ever programme to raise awareness, diagnose and treat breast cancer in Ethiopia. The interim results of this five-year initiative are reported in the March edition of Clinical Oncology *. Tue, 11 Mar 2008 10:00:00 GMT http://www.astrazeneca.com/?itemId=3892322 2008-03-11T10:00:00Z http://www.astrazeneca.com/?itemId=3892327 AstraZeneca has today published its Annual Report and Form 20-F Information 2007. The Report is available as a dedicated website at: www.astrazeneca.com/annualreport2007 (which includes a downloadable PDF version) and as a printed document. Our summary corporate responsibility (CR) report has been integrated into the Report and full CR information continues to be available online at: www.astrazeneca.com/responsibility . Thu, 06 Mar 2008 00:00:00 GMT http://www.astrazeneca.com/?itemId=3892327 2008-03-06T00:00:00Z http://www.astrazeneca.com/?itemId=3892272 AstraZeneca today announced submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once-daily SEROQUEL XR™ (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients. Fri, 29 Feb 2008 00:00:00 GMT http://www.astrazeneca.com/?itemId=3892272 2008-02-29T00:00:00Z http://www.astrazeneca.com/?itemId=3892282 AstraZeneca today announced that, under the provisions of the agreements relating to the restructuring of the AstraZeneca and Merck & Co. joint venture in the United States, AstraZeneca has been informed that Merck has elected not to exercise the First Option related to the relinquishment of Merck’s rights over the products not covered by the Partial Retirement (see paragraph below), other than Nexium™ and Prilosec™. As a result of this decision, contingent payments will continue on the products Thu, 28 Feb 2008 00:00:00 GMT http://www.astrazeneca.com/?itemId=3892282 2008-02-28T00:00:00Z http://www.astrazeneca.com/?itemId=3892274 AstraZeneca today announced that its HORIZON III Phase II/III head-to-head study of RECENTIN™ (cediranib, AZD2171) with chemotherapy versus bevacizumab (Avastin™) with chemotherapy in patients with first line metastatic colorectal cancer (CRC) will be progressing directly into Phase III at 20mg. Patients will also continue to be recruited at 20mg into the first line CRC HORIZON II study of RECENTIN with chemotherapy versus chemotherapy alone. Wed, 27 Feb 2008 00:00:00 GMT http://www.astrazeneca.com/?itemId=3892274 2008-02-27T00:00:00Z http://www.astrazeneca.com/?itemId=3892268 AstraZeneca today announced it intends to seek reconsideration or reversal of a verdict in the Montgomery County Circuit Court awarding $40 million in compensatory damages and $175 million in punitive damages for alleged false and misleading reporting of prices for drugs reimbursed by the Alabama State Medicaid Agency in the US. Fri, 22 Feb 2008 00:00:00 GMT http://www.astrazeneca.com/?itemId=3892268 2008-02-22T00:00:00Z http://www.astrazeneca.com/?itemId=3892284 AstraZeneca today announced that Jean-Philippe Courtois is to join the Board of Directors as a Non-Executive Director with immediate effect. Jean-Philippe Courtois is currently President of Microsoft International, a territory that spans 100 subsidiaries operating in over 240 countries outside the United States and Canada, and a Senior Vice-President of Microsoft Corporation. Mon, 18 Feb 2008 11:00:00 GMT http://www.astrazeneca.com/?itemId=3892284 2008-02-18T11:00:00Z http://www.astrazeneca.com/?itemId=3892270 AstraZeneca and Nomura Phase4 Ventures today announced the signing of a deal to form Albireo, a company focused on developing new treatments for gastrointestinal (GI) disorders. Thu, 14 Feb 2008 00:00:00 GMT http://www.astrazeneca.com/?itemId=3892270 2008-02-14T00:00:00Z http://www.astrazeneca.com/?itemId=3892279 AstraZeneca today announced that the company has submitted applications in the European Union (EU) under the Mutual Recognition Procedure (MRP) for once-daily SEROQUEL XR™ (quetiapine fumarate) Extended-Release Tablets, seeking approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder. This follows two supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA), announced in January, Mon, 11 Feb 2008 00:00:00 GMT http://www.astrazeneca.com/?itemId=3892279 2008-02-11T00:00:00Z http://www.astrazeneca.com/?itemId=3892276 AstraZeneca PLC announced today that its biologics division, MedImmune, had submitted a Biologics License Application (BLA) to the U.S. Food & Drug Administration (FDA) for motavizumab, an investigational monoclonal antibody (MAb) derived from recombinant DNA technology. Mon, 04 Feb 2008 00:00:00 GMT http://www.astrazeneca.com/?itemId=3892276 2008-02-04T00:00:00Z http://www.astrazeneca.com/?itemId=3892242 AstraZeneca corporate information, one of the world's leading pharmaceutical companies providing effective prescription drugs and innovative prescription medicines in many important therapeutic areas Thu, 31 Jan 2008 00:00:00 GMT http://www.astrazeneca.com/?itemId=3892242 2008-01-31T00:00:00Z http://www.astrazeneca.com/?itemId=3892246 AstraZeneca China has agreed to become a major sponsor of the UK Pavilion at Shanghai Expo 2010. AstraZeneca’s sponsorship will amount to £500,000 and will directly support the design, development and staging of the British pavilion. Mon, 21 Jan 2008 00:00:00 GMT http://www.astrazeneca.com/?itemId=3892246 2008-01-21T00:00:00Z http://www.astrazeneca.com/?itemId=3892244 AstraZeneca today announced the launch of a new clinical trial, SATURN, designed to measure the impact of CRESTOR™ (rosuvastatin) 40 mg and atorvastatin (Lipitor®) 80 mg on the progression of atherosclerosis in high risk patients. SATURN will compare the effects of these two statins on the ability to decrease progression or induce regression of atherosclerosis, the main cause of cardiovascular disease, following two years of treatment in patients with coronary artery disease. Tue, 15 Jan 2008 00:00:00 GMT http://www.astrazeneca.com/?itemId=3892244 2008-01-15T00:00:00Z http://www.astrazeneca.com/?itemId=3892240 AstraZeneca today announced that the company has submitted two separate supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) for once-daily SEROQUEL XR™ (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder. Wed, 02 Jan 2008 00:00:00 GMT http://www.astrazeneca.com/?itemId=3892240 2008-01-02T00:00:00Z http://www.astrazeneca.com/?itemId=4369685 http://www.astrazeneca.com/?itemId=4369685 http://www.astrazeneca.com/?itemId=4084115 http://www.astrazeneca.com/?itemId=4084115 http://www.astrazeneca.com/?itemId=3892286 http://www.astrazeneca.com/?itemId=3892286 http://www.astrazeneca.com/?itemId=3892234 http://www.astrazeneca.com/?itemId=3892234 http://www.astrazeneca.com/?itemId=3892292 http://www.astrazeneca.com/?itemId=3892292 http://www.astrazeneca.com/?itemId=3892256 http://www.astrazeneca.com/?itemId=3892256 http://www.astrazeneca.com/?itemId=3892304 http://www.astrazeneca.com/?itemId=3892304 http://www.astrazeneca.com/?itemId=3892248 http://www.astrazeneca.com/?itemId=3892248 http://www.astrazeneca.com/?itemId=3892316 http://www.astrazeneca.com/?itemId=3892316 http://www.astrazeneca.com/?itemId=3892266 http://www.astrazeneca.com/?itemId=3892266 http://www.astrazeneca.com/?itemId=3892238 http://www.astrazeneca.com/?itemId=3892238